Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet

Industry Leaders Share Their Equity And Sustainability Aspirations

Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.  

Scrip Asks, Part 7
• Source: Alamy

The final installation of our series looking at industry leaders’ expectations for the year ahead focuses on sustainability and equity: in health care, in companies and across society as a whole.

Tom Oakley, CEO of medical imaging software and systems specialist Feedback plc, summed up a broad perspective shared by several...

More from Scrip Asks

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?